[Comparison of clinical outcomes between neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis].

PubMed 2026

View at publisher
Authors: H L Liu, L N Wu, C D Sun, H Zou, L C Cha, F B Qiu, B Zhou
DOI: 10.3760/cma.j.cn112139-20250709-00343
Cited by: 1

Abstract

Based on the current best available evidence from RCT,for resectable pancreatic cancer, neoadjuvant therapy improves the R0 resection rate and pN0 rate without increasing postoperative complications or mortality compared to the traditional approach of upfront surgery. However,these findings warrant further validation by more high-quality RCT.

Fields of Study & Subjects

Pancreatic and Hepatic Oncology Research Economic and Financial Impacts of Cancer Cholangiocarcinoma and Gallbladder Cancer Studies

Publication details

Journal / source
PubMed
Volume
64
Issue
2
Pages
159–167
Publication date
1 February 2026
Language
ZH